Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 3/20 | 0.45 |
| ▸ | CCR1 | P32246 | 3/20 | 0.40 |
| ▸ | HPGDS | O60760 | 7/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | FCER2 | P06734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028423 | 0.93 | CDC7 (0.42) | PYGLCCR1HPGDSCTSD | |
| SCHEMBL20028427 | 0.91 | PYGL (0.41) | PYGLCCR1HPGDSCNR1EGLN2 | |
| SCHEMBL22886770 | 0.88 | PYGL (0.38) | PYGLCCR1EGLN2EGLN1GAA | |
| SCHEMBL22886428 | 0.88 | PYGL (0.48) | PYGLEGLN2EGLN1GAA | |
| SCHEMBL20028429 | 0.86 | PYGL (0.42) | PYGLCCR1HPGDSCTSD | |
| SCHEMBL20028424 | 0.83 | PYGL (0.40) | PYGLCCR1HPGDS | |
| SCHEMBL21854063 | 0.82 | CAPN1 (0.53) | — | |
| SCHEMBL20028431 | 0.82 | CAPN1 (0.53) | — | |
| SCHEMBL22886430 | 0.82 | PYGL (0.41) | PYGLCCR1HPGDSEGLN2EGLN1 | |
| SCHEMBL22886426 | 0.80 | FTO (0.42) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | PYGL 719/4885CCR1 3791/4885HPGDS 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.